The work of the

WRLFMD in relation to

regional networks

Reference Laboratory for FMDV

WRLFMD - GOODBYE TO:

Nigel Ferris – January 2012

Yanmin Li – August 2013

Geoff Hutchings – July 2012 Claudia Doel– March 2013

Miki Madi – June 2013 Jef Hammond – July 2013

WRLFMD NOW David Paton

Don King

Nick Knowles

Jemma Wadsworth Kasia Bankowska Begoña Valdazo-Gonzalez Graham Freimanis

David King

SEQUENCING

NGS VP1 FGS

Bob Statham

Anna Ludi

Ginny Wilsden Pip Hamblin Kelly Adams Abid Bin Tarif

SEROLOGY

VM PTS

Valérie Mioulet

Britta Wood Ashley Gray Veronica Fowler Bryony Armson

Barsha Thappa Vacancy

VIROLOGY

John Bashiruddin

Debi Gibson KITS

Dx/R Dx/R Dx/R R

COUNTRIES

Sri Lanka

Bhutan

Hong Kong SAR

Viral sequences

Clinical samples

October 2012 - October 2013

Reports for these samples can be found at www.wrlfmd.org

PAT

Pool 7

Pool 5

Pool 4

Pool 6

Pool 3

Pool 2

Pool 1

RESULTS FOR SAMPLES SUBMITTED TO WRLFMD IN

THE PAST 12 MONTHS

O

A

SAT 1

SAT 2

ASIA-1

NVD

Total: 337 samples submitted and processed (46 in progress)

219 isolates

269 samples collected in 2013

rRT-PCR: 260 positive (79%)

NVD = no virus detected (negative by VI and Ag-ELISA)

Si Lanka

Bhutan

Hong Kong SAR

FMDV type O FMDV type A

PAT

FMDV type SAT1 FMDV type SAT2

FMDV type Asia-1

RESULTS FOR SAMPLES SUBMITTED TO WRLFMD IN

THE PAST 12 MONTHS

TRAINING HELD AT WRLFMD, PIRBRIGHT

Year Participants Course Countries

2013 7 Diagnostic course Brazil, Jordan, New-Zealand, Tanzania, Uganda, Zambia, Zimbabwe

2013 3 Vaccine matching workshop USA

2012 8 Diagnostic course Brazil, Ethiopia, New-Zealand, Spain, Uganda, Zimbabwe

2011 6 Diagnostic course New Zealand, Nigeria, Russia, Sudan, Uganda

2011 8 Vaccine matching workshop Belgium, Kenya, Russia, Nigeria, Thailand, Botswana

• Prepared and shipped out annually

• 1977 - Results from Phase I reported in Brescia:

• 21 laboratories participated

• Compared VI and VNT methods

• Reported issues in logistics and sample shipment

• 2005 – Pilot study with 5 labs to test feasibility of including virus detection assays (VI and RT-PCR)

• 2005-6 – Phase XIX to include molecular assays for virus detection

• 2013 – Phase XXVI

PROFICIENCY TEST (PTS)

• Participants supplied with up to 4 separate panels:

– Panel 1: infectious material from 2 cases of suspected

vesicular disease for virus detection (FMDV and SVDV)

– Panel 2: non-infectious material from cattle or pigs for virus

genome/antigen detection (FMDV and SVDV)

– Panel 3: non-infectious material for FMD serology

– Panel 4: non-infectious material for SVD serology

• Each sample is randomly assigned a number and

labeled accordingly

PTS – CURRENT FORMAT

• 76 laboratories in 72 countries invited

• 57 laboratories in 54 countries received at least one

panel

• Results returned:

PTS 2012 participation

© d

- m a p s . c

o m

EU and acceding member countries (26)

EUFMD sponsored countries (18)

Self-funded countries (10)

(where panels were sent but no results

returned, country is not counted as a

participant (6))

Infectious material from 2 cases of suspected vesicular disease

for virus detection (FMDV and SVDV):

PTS 2012 RESULTS – PANEL 1

VI and Ag-ELISA

Molecular assays

0

20

40

60

80

100

EU

(n=

12)

EU

FM

D (

n=

6)

Oth

er

(n=

5)

EU

(n=

12)

EU

FM

D (

n=

6)

Oth

er

(n=

5)

EU

(n=

12)

EU

FM

D (

n=

6)

Oth

er

(n=

5)

EU

(n=

12)

EU

FM

D (

n=

6)

Oth

er

(n=

5)

EU

(n=

12)

EU

FM

D (

n=

6)

Oth

er

(n=

5)

EU

(n=

12)

EU

FM

D (

n=

6)

Oth

er

(n=

5)

Epi FMDV O SKR/4/2010

Epi -ve Faeces FMDV O SKR/4/2010

Epi SVDV ITL/7/07

Epi -ve2 Faeces SVDV ITL/8/07

Co

rrect

resu

lts (

%)

Panel 1 - Overall results

PTS 2012 RESULTS – PANEL 2 Non-infectious material from cattle or pigs for virus genome/antigen detection

(FMDV and SVDV)

0

20

40

60

80

100

EU

EU

FM

D

Oth

er

EU

EU

FM

D

Oth

er

EU

EU

FM

D

Oth

er

EU

EU

FM

D

Oth

er

EU

EU

FM

D

Oth

er

EU

EU

FM

D

Oth

er

FMD O Pak/28/2010 FMD A Tur/28/2010 FMD Sat 2 Bot/2/2010

SVD ITL/07/07 Asia 1 Bar 9/2009 MEM

Co

rrect

resu

lts (

%)

Panel 2 results

Ag-ELISA and LFD (EU n=20; EUFMD n=10; Other n=9)

Molecular assays (EU n=24; EUFMD n=11; Other n=8)

• 86 countries/labs invited

• 61 countries/labs requested participation

• 54 shipments sent out over August-October

• 45 confirmations of receipt (only)

• 40 sets of results received so far

PTS 2013 SO FAR…

© d

- m a p s . c

o m

Panels requested 2013:

EU and acceding member countries (26)

EUFMD sponsored countries (22)

Self-funded countries (8)

FMD regional labs

• Under-represented pools/countries: increase sample numbers or reports/results

• Training: more targeted to needs and individual labs.

• PTS:

• increase participation from regional ref labs and other labs.

• improve feedback, should be as practical as reasonably possible.

• QA and biosecurity processes:

• improve in local labs without it becoming an unreasonable burden. Good processes more important than accreditation.

• improve understanding of the processes required for international shipments of infectious and potentially infectious material. What do the regulations mean in practice?

• Keep improving and updating lab and field assays. Must be as practical as needed by the different end-users (vets, labs…).

• Improve access to and dissemination of information whilst ensuring that it is not corrupted (sequence database).

WISH LIST